OP0595 is a novel diazabicyclooctane which, like avibactam, inhibits class A and C ␤-lactamases. In addition, unlike avibactam, it has antibacterial activity, with MICs of 0.5 to 4 g/ml for most members of the family Enterobacteriaceae, owing to inhibition of PBP2; moreover, it acts synergistically with PBP3-active ␤-lactams independently of ␤-lactamase inhibition, via an "enhancer effect." Enterobacteriaceae mutants stably resistant to 16 g/ml OP0595 were selected on agar at frequencies of approximately 10 ؊7 . Unsurprisingly, OP0595 continued to potentiate substrate ␤-lactams against mutants derived from Enterobacteriaceae with OP0595-inhibited class A and C ␤-lactamases. Weaker potentiation of partners, especially aztreonam, cefepime, and piperacillin-less so meropenem-remained frequent for OP0595-resistant Enterobacteriaceae mutants lacking ␤-lactamases or with OP0595-resistant metallo-␤-lactamases (MBLs), indicating that the enhancer effect is substantially retained even when antibiotic activity is lost.
RESULTS

Selection and phenotypes of OP0595-resistant mutants. OP0595-resistant mutants were readily selected from all 82 parent strains, with frequencies approximately 10
Ϫ7 . Five morphologically diverse mutants were retained per selection and subjected to susceptibility testing. Subsequent exclusions (e.g., for loss of resistance or as suspected contaminants) amounted to just 16 of these 410 (82 ϫ 5) organisms, and for most parents, the full complement of five mutants was retained.
MICs of OP0595 for mutants rose from the parental values of 0.5 to 4 g/ml to 8 to Ͼ32 g/ml, with 381/394 (96.7%) values of Ͼ32 g/ml. MIC changes for comparator antibiotics are shown in Table 2 for 93 mutants derived from the 19 ␤-lactam-susceptible parent strains. Among these 93 mutants, 81 had Ͼ128-fold MIC rises for amdinocillin, and 81 had small (mostly 2-to 4-fold) increases for imipenem; shifts for other comparators were scattered around unity (i.e., with similar proportions showing MIC decreases as increases). Analysis is more complex for mutants derived from strains with extended-spectrum ␤-lactamase (ESBLs), AmpC enzymes, or carbapenemases because many "starting" MICs for the parent organisms were off-scale, precluding calculation of fold change. Nevertheless, amdinocillin remained the sole agent, besides OP0595 itself, for which large MIC increases were widespread (not shown).
OP0595 combinations versus mutants of control strains. OP0595 at concentrations of 2 to 8 g/ml (1 to 4 g/ml with aztreonam) caused widespread potentiation of piperacillin, aztreonam, and cefepime, less so meropenem, against OP0595-selected mutants of cephalosporin-and carbapenem-susceptible control strains (Table 3) . At 1 to 4 g/ml, it reduced the modal MIC of aztreonam from 0.12 g/ml to Յ0.016 g/ml and that of piperacillin from 2 g/ml to 0.25 g/ml. The modal MICs of unprotected cefepime and meropenem were only 2-fold above the lowest concentration tested, precluding precise estimation of MIC reductions; nevertheless, more than 85% of cefepime MICs were reduced to Յ0.016 g/ml by OP0595 at 2 to 8 g/ml, whereas meropenem MICs were less consistently lowered. Potentiation of piperacillin for Klebsiella pneumoniae may have partly reflected inhibition of the chromosomal penicillinases that are universal in the species (12) , but this cannot explain potentiation for other species, which lack these enzymes, nor potentiation of the other test ␤-lactams, which are not labile to K. pneumoniae penicillinases. Less synergy was seen between ceftazidime and avibactam (4 g/ml), with MICs generally lowered by only one doubling dilution.
OP0595 combinations versus mutants of strains with class A and C ␤-lactamases. ESBLs, K. pneumoniae carbapenemases (KPCs), and AmpC enzymes are inhibited by diazabicyclooctanes (1, 13, 14) , and OP0595 continued to strongly potentiate its partner ␤-lactams against mutants whenever the partner was a good substrate of the ␤-lactamase produced-i.e., piperacillin, cefepime, and aztreonam for mutants with ESBLs, piperacillin and aztreonam for those with AmpC, and all four ␤-lactams for those with KPC enzymes (Table 4) . Avibactam (4 g/ml) likewise potentiated ceftazidime against these organisms, a result in keeping with published data (15) (16) (17) .
Potentiation was weaker when OP0595 was combined with weak substrates or stable agents. Nevertheless, two-to fourfold reductions in meropenem MICs were widespread for ESBL and AmpC producers, and the geometric mean MIC of cefepime for AmpC producers was reduced from 0.51 g/ml to Յ0.016 g/ml by OP0595 at 2 to 8 g/ml.
OP0595 combinations versus mutants of strains with MBLs. Among the 18 parent strains with IMP, NDM, and VIM metallocarbapenemases, six were susceptible to aztreonam at Յ0.25 g/ ml, indicating the absence of ESBL or AmpC activity that might be inhibited by OP0595. MIC distributions of diazabicyclooctane combinations for mutants of all 18 strains are summarized in Table 5 ; the MICs for mutants of the aztreonam-susceptible strains are listed in full in Table 6 . Potentiation by OP0595 was widespread and, for the aztreonam-resistant organisms, probably largely reflected inhibition of coproduced class A and C enzymes. However, inhibition of secondary enzymes cannot explain the frequent (not universal, even within series) 2-to 16-fold synergy observed between OP0595 and both aztreonam and cefepime for OP0595-resistant mutants of the aztreonam-susceptible strains ( Table 6 ). Potentiation of meropenem was less frequent, being almost exclusive to E. coli H112760544 and H112760545. No similar potentiation of ceftazidime by avibactam was seen for mutants of aztreonam-susceptible metallo-␤-lactamase (MBL) producers. Table 7 . These mutants, like their parents, were highly resistant to piperacillin, with MICs of Ͼ64 g/ml. This resistance was strongly reversed so that, with OP0595 at 8 g/ml, the modal piperacillin MIC was reduced to 1 g/ml, with no value of Ͼ8 g/ml. Resistance to aztreonam, cefepime, and ceftazidime was more variable, probably reflecting the presence or absence of ESBL; nevertheless, potentiation of aztreonam and cefepime by OP0595 and of ceftazidime by avibactam was universal. Potentiation of meropenem by OP0595 was weaker than for other partner ␤-lactams.
DISCUSSION
OP0595 has MICs of 0.5 to 4 g/ml for most E. coli, Klebsiella, Enterobacter, and Citrobacter isolates (1, 2), but this activity, which reflects attack on PBP2, is vulnerable to mutational resistance (1). Consequently, it is more appropriate to use OP0595 in combinations of drugs than to use it as a single agent, thereby also exploiting its ␤-lactamase inhibitor and enhancer activities. Evaluation of these activities is, however, complicated by the antibacterial activity, and to elucidate them independently, we studied the behavior of OP0595-resistant mutants.
Unsurprisingly, OP0595's ␤-lactamase inhibitor activity was not contingent on its antibacterial activity, and the molecule continued to strongly potentiate substrate ␤-lactams against OP0595-resistant mutants of strains with class A and C ␤-lactamases (Table  4) , which are strongly inhibited (1). Avibactam similarly potentiated ceftazidime against these organisms. Second, and less predictably, OP0595's enhancer activity also proved substantially independent of direct antibacterial activity, with frequent potentiation of aztreonam, cefepime, and piperacillin against mutants of control strains, which lacked ␤-lactamases (Table 3) , and of a GM, geometric mean; Max, maximum. MICs of Ͼ256 g/ml were counted as 512 g/ml when calculating geometric means, and MICs of Յ0.016 were counted as 0.014 g/ml. b The geometric mean and maximum MIC of drugs alone or in combination with the OP0595 diazabicyclooctane are shown. All MICs are shown in micrograms per milliliter with and without OP0595 at 2, 4, and 8 g/ml (0 for no OP0595). The geometric mean and maximum MIC of ceftazidime alone and with avibactam (4 g/ml) are shown for comparison.
both cefepime and aztreonam against mutants of aztreonam-susceptible MBL producers, which were inferred to lack enzymes likely to be inhibited by OP0595. Potentiation of meropenem was weaker or absent probably because it, unlike aztreonam and cefepime, has significant affinity for PBP2 (18) . There was no similar enhancer effect for avibactam. Mutant-to-mutant variation in the extent of the enhancer effect (Tables 3 and 6 ) and in MIC shifts for ␤-lactams besides amdinocillin (Table 2 ) may reflect diversity in the underlying mechanisms. Aside from OP0595 resistance, their most consistent trait was sharply increased resistance to amdinocillin, which solely targets PBP2, and smaller MIC increases for imipenem, which primarily targets PBP2 (18, 19) . Recent studies show that amdinocillin selects diverse mutations, mostly upregulating the stringent response and increasing cellular levels of guanosine tetraphosphate (20) , and preliminary data suggest similar patterns among the present OP0595-selected mutants (21) . Changes to pbp2 itself are rare or absent. It is unclear how ppGpp-induced changes protect against PBP2-active agents (20, 22) , but it is most plausible that they are somehow compensatory. Notably, amdinocillin-and OP0595-resistant mutants grow as stable round forms under amdinocillin or OP0595 challenge (1, 6, 23) , indicating that PBP2 itself remains vulnerable, an observation keeping with the retention of the enhancer effect.
The ease with which OP0595-resistant mutants could be selected begs the question of whether they will be a clinical problem. This cannot be answered definitively, but again, insight is provided by the recent work of Thulin et al. (20) with amdinocillin, which showed that that, whereas laboratory-selected amdinocillin-resistant mutants were diverse, amdinocillin-resistant clinical isolates of E. coli consistently had a cysB mutation, implying that many other mutant types might be less competitive. This view was supported by competition and growth rate studies, and it is hard to believe that bacteria retain full virulence once their cell shape is grossly distorted by continued attack on PBP2. There has been little accumulation of amdinocillin-resistant E. coli in Scandinavia, where the drug is widely used (24) , but this may reflect good stewardship and use mostly in low-risk cystitis patients.
An obvious route to lower the risk of OP0595 resistance in Enterobacteriaceae would be to combine it with aztreonam, ensuring activity against MBL producers irrespective of the enhancer effect. Nevertheless, the enhancer effect with cefepime and piperacillin is striking and often allowed retention of activity, even at EUCAST's low breakpoints, against OP0595-resistant mutants of strains with MBLs or OXA-48-like enzymes. Such combinations would allow better anti-Pseudomonas coverage than aztreonam-OP0595. Last, although potentiation of meropenem for OP0595 was weaker than for PBP3-directed partners, meropenem has the broadest antibacterial spectrum of the four partners tested here, meaning that it continues to merit consideration. a The MICs of piperacillin, cefepime, etc., are shown. The geometric mean (GM) and percent susceptible (%S) at current EUCAST susceptibility breakpoints for the unprotected compounds are shown. The current EUCAST susceptibility breakpoints for the unprotected compounds are 1 g/ml for aztreonam, cefepime, and ceftazidime, 2 g/ml for meropenem, and 8 g/ml for piperacillin. MICs of Ͼ256 g/ml were counted as 512 g/ml when calculating geometric means, and MICs of Յ0.016 were counted as 0.014 g/ml.
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